Disc Medicine - Best comparison stock to Clinuvel, page-35

Understand there are a few frustrated holders- especially recent holders in the red. The news flow is certainly down on this time period last year. 2 newsletters of little material information (IMO) is not much since the AGM. The list of goals is there for everyone to see so I hope the news comes forth soon. Unfortunately, as discussed, the additional revenue streams everyone is waiting for might be sometime off? The best we can hope for is some additional EPP sales. I can't see Cyacelle doing much so I hope they fast track into other OTC lines. The adolescent extension for EPP should help but now we at mercy of regulators as to timing. The DMF for ACTH is important but again what's the time frame? They seem to be working on it now for some time. It's not an easy one -according to some stat I read there's not much success on initial submissions (1%). So important they get it as right as possible. I feel this year we need some good updates from all the trials and a little more action from the marketing team with the OTC's. Half year in a couple of weeks so if nothing till then we should get a comprehensive update? GLTA